Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 51 entries
Sorted by: Best Match Show Resources per page
[Dealing with therapeutic drugs].

Der Internist

Herken H, Dölle W.
PMID: 3288572
Internist (Berl). 1988 Mar;29(3):141-6.

No abstract available.

Cite
Herken H, Dölle W. Vom Umgang mit Arzneimitteln. [Dealing with therapeutic drugs]. Internist (Berl). 1988;29(3):141-6
Herken, H., & Dölle, W. (1988). Vom Umgang mit Arzneimitteln. [Dealing with therapeutic drugs]. Der Internist, 29(3), 141-6.
Herken, H, and Dölle, W. "Vom Umgang mit Arzneimitteln." [Dealing with therapeutic drugs]. Der Internist vol. 29,3 (1988): 141-6.
Herken H, Dölle W. Vom Umgang mit Arzneimitteln. [Dealing with therapeutic drugs]. Internist (Berl). 1988 Mar;29(3):141-6. German. PMID: 3288572.
Copy Download .nbib Format: NLM
Clinical calculations.

Nursing

Daniels JM, Smith LM.
PMID: 2366980
Nursing. 1990 Jul;20(7):78-9. doi: 10.1097/00152193-199007000-00031.

No abstract available.

Cite
Daniels JM, Smith LM. Clinical calculations. Nursing. 1990;20(7):78-9doi: 10.1097/00152193-199007000-00031.
Daniels, J. M., & Smith, L. M. (1990). Clinical calculations. Nursing, 20(7), 78-9. https://doi.org/10.1097/00152193-199007000-00031
Daniels, J M, and Smith, L M. "Clinical calculations." Nursing vol. 20,7 (1990): 78-9. doi: https://doi.org/10.1097/00152193-199007000-00031
Daniels JM, Smith LM. Clinical calculations. Nursing. 1990 Jul;20(7):78-9. doi: 10.1097/00152193-199007000-00031. PMID: 2366980.
Copy Download .nbib Format: NLM
The effects of industry sponsorship on comparator selection in trial registrations for neuropsychiatric conditions in children.

PloS one

Dunn AG, Mandl KD, Coiera E, Bourgeois FT.
PMID: 24376857
PLoS One. 2013 Dec 23;8(12):e84951. doi: 10.1371/journal.pone.0084951. eCollection 2013.

Pediatric populations continue to be understudied in clinical drug trials despite the increasing use of pharmacotherapy in children, particularly with psychotropic drugs. Most pertinent to the clinical selection of drug interventions are trials directly comparing drugs against other drugs....

Cite
Dunn AG, Mandl KD, Coiera E, et al. The effects of industry sponsorship on comparator selection in trial registrations for neuropsychiatric conditions in children. PLoS One. 2013;8(12):e84951doi: 10.1371/journal.pone.0084951.
Dunn, A. G., Mandl, K. D., Coiera, E., & Bourgeois, F. T. (2013). The effects of industry sponsorship on comparator selection in trial registrations for neuropsychiatric conditions in children. PloS one, 8(12), e84951. https://doi.org/10.1371/journal.pone.0084951
Dunn, Adam G, et al. "The effects of industry sponsorship on comparator selection in trial registrations for neuropsychiatric conditions in children." PloS one vol. 8,12 (2013): e84951. doi: https://doi.org/10.1371/journal.pone.0084951
Dunn AG, Mandl KD, Coiera E, Bourgeois FT. The effects of industry sponsorship on comparator selection in trial registrations for neuropsychiatric conditions in children. PLoS One. 2013 Dec 23;8(12):e84951. doi: 10.1371/journal.pone.0084951. eCollection 2013. PMID: 24376857; PMCID: PMC3871546.
Copy Download .nbib Format: NLM
[Modern principles of drug therapy of peptic ulcer].

Klinicheskaia meditsina

Sheptulin AA.
PMID: 9036199
Klin Med (Mosk). 1996;74(8):17-9.

No abstract available.

Cite
Sheptulin AA. Sovremennye printsipy farmakoterapii iazvennoi bolezni. [Modern principles of drug therapy of peptic ulcer]. Klin Med (Mosk). 1996;74(8):17-9
Sheptulin, A. A. (1996). Sovremennye printsipy farmakoterapii iazvennoi bolezni. [Modern principles of drug therapy of peptic ulcer]. Klinicheskaia meditsina, 74(8), 17-9.
Sheptulin, A A. "Sovremennye printsipy farmakoterapii iazvennoi bolezni." [Modern principles of drug therapy of peptic ulcer]. Klinicheskaia meditsina vol. 74,8 (1996): 17-9.
Sheptulin AA. Sovremennye printsipy farmakoterapii iazvennoi bolezni. [Modern principles of drug therapy of peptic ulcer]. Klin Med (Mosk). 1996;74(8):17-9. Russian. PMID: 9036199.
Copy Download .nbib Format: NLM
[Science in taking medicine].

[Hokkaido igaku zasshi] The Hokkaido journal of medical science

Yoshioka M, Sugiyama T, Yamaguchi E, Sugihara T.
PMID: 12911003
Hokkaido Igaku Zasshi. 2003 Jul;78(4):285-7.

It is a well-known fact that medicine plays an important role in treatment of several diseases. New development of many drugs led to not only benefits but also unexpected damage to human beings. In Japan, we are plunged into...

Cite
Yoshioka M, Sugiyama T, Yamaguchi E, et al. [Science in taking medicine]. Hokkaido Igaku Zasshi. 2003;78(4):285-7
Yoshioka, M., Sugiyama, T., Yamaguchi, E., & Sugihara, T. (2003). [Science in taking medicine]. [Hokkaido igaku zasshi] The Hokkaido journal of medical science, 78(4), 285-7.
Yoshioka, Mitsuhiro, et al. "[Science in taking medicine]." [Hokkaido igaku zasshi] The Hokkaido journal of medical science vol. 78,4 (2003): 285-7.
Yoshioka M, Sugiyama T, Yamaguchi E, Sugihara T. [Science in taking medicine]. Hokkaido Igaku Zasshi. 2003 Jul;78(4):285-7. Japanese. PMID: 12911003.
Copy Download .nbib Format: NLM
Advanced and controlled drug delivery systems in clinical disease management.

Pharmacy world & science : PWS

Brouwers JR.
PMID: 8933575
Pharm World Sci. 1996 Oct;18(5):153-62. doi: 10.1007/BF00820726.

Advanced and controlled drug delivery systems are important for clinical disease management. In this review the most important new systems which have reached clinical application are highlighted. Microbiologically controlled drug delivery is important for gastrointestinal diseases like ulcerative colitis...

Cite
Brouwers JR. Advanced and controlled drug delivery systems in clinical disease management. Pharm World Sci. 1996;18(5):153-62doi: 10.1007/BF00820726.
Brouwers, J. R. (1996). Advanced and controlled drug delivery systems in clinical disease management. Pharmacy world & science : PWS, 18(5), 153-62. https://doi.org/10.1007/BF00820726
Brouwers, J R. "Advanced and controlled drug delivery systems in clinical disease management." Pharmacy world & science : PWS vol. 18,5 (1996): 153-62. doi: https://doi.org/10.1007/BF00820726
Brouwers JR. Advanced and controlled drug delivery systems in clinical disease management. Pharm World Sci. 1996 Oct;18(5):153-62. doi: 10.1007/BF00820726. PMID: 8933575.
Copy Download .nbib Format: NLM
Patient group directions.

Nursing times

Spyropoulos A.
PMID: 11917395
Nurs Times. 2002 Feb 28-Mar 6;98(9):48.

No abstract available.

Cite
Spyropoulos A. Patient group directions. Nurs Times. 2002;98(9):48
Spyropoulos, A. (2002). Patient group directions. Nursing times, 98(9), 48.
Spyropoulos, Andrea. "Patient group directions." Nursing times vol. 98,9 (2002): 48.
Spyropoulos A. Patient group directions. Nurs Times. 2002 Feb 28-Mar 6;98(9):48. PMID: 11917395.
Copy Download .nbib Format: NLM
Necessity and requirements of bridging studies and their present status in Japan.

International journal of clinical pharmacology and therapeutics

Naito C.
PMID: 10706195
Int J Clin Pharmacol Ther. 2000 Feb;38(2):80-6. doi: 10.5414/cpp38080.

The mainstays of the harmonized final document about ethnic factors in the acceptability of foreign clinical data include a complete clinical data package and a bridging study (for efficacy and/or for safety). A clinical data package that meets all...

Cite
Naito C. Necessity and requirements of bridging studies and their present status in Japan. Int J Clin Pharmacol Ther. 2000;38(2):80-6doi: 10.5414/cpp38080.
Naito, C. (2000). Necessity and requirements of bridging studies and their present status in Japan. International journal of clinical pharmacology and therapeutics, 38(2), 80-6. https://doi.org/10.5414/cpp38080
Naito, C. "Necessity and requirements of bridging studies and their present status in Japan." International journal of clinical pharmacology and therapeutics vol. 38,2 (2000): 80-6. doi: https://doi.org/10.5414/cpp38080
Naito C. Necessity and requirements of bridging studies and their present status in Japan. Int J Clin Pharmacol Ther. 2000 Feb;38(2):80-6. doi: 10.5414/cpp38080. PMID: 10706195.
Copy Download .nbib Format: NLM
Intelligent risk communication: can it be improved?.

Drug safety

Czarnecki A.
PMID: 18095742
Drug Saf. 2008;31(1):1-6. doi: 10.2165/00002018-200831010-00001.

Every year, regulators and scientists from academia and industry invest considerable time and effort into drug development, the assessment of safety, and subsequent risk-benefit communication. The observation of everyday medical practice, lay press releases and drug information indicates that...

Cite
Czarnecki A. Intelligent risk communication: can it be improved?. Drug Saf. 2008;31(1):1-6doi: 10.2165/00002018-200831010-00001.
Czarnecki, A. (2008). Intelligent risk communication: can it be improved?. Drug safety, 31(1), 1-6. https://doi.org/10.2165/00002018-200831010-00001
Czarnecki, Andrzej. "Intelligent risk communication: can it be improved?." Drug safety vol. 31,1 (2008): 1-6. doi: https://doi.org/10.2165/00002018-200831010-00001
Czarnecki A. Intelligent risk communication: can it be improved?. Drug Saf. 2008;31(1):1-6. doi: 10.2165/00002018-200831010-00001. PMID: 18095742.
Copy Download .nbib Format: NLM
The importance of hormesis to public health.

Ciencia & saude coletiva

Cook R, Calabrese EJ.
PMID: 17680154
Cien Saude Colet. 2007 Jul-Aug;12(4):955-63. doi: 10.1590/s1413-81232007000400017.

Hormesis is a specific type of nonmonotonic dose response whose occurrence has been documented across a broad range of biological models and diverse types of exposure. The effects that occur at various points along this curve can be interpreted...

Cite
Cook R, Calabrese EJ. The importance of hormesis to public health. Cien Saude Colet. 2007;12(4):955-63doi: 10.1590/s1413-81232007000400017.
Cook, R., & Calabrese, E. J. (2007). The importance of hormesis to public health. Ciencia & saude coletiva, 12(4), 955-63. https://doi.org/10.1590/s1413-81232007000400017
Cook, Ralph, and Calabrese, Edward J. "The importance of hormesis to public health." Ciencia & saude coletiva vol. 12,4 (2007): 955-63. doi: https://doi.org/10.1590/s1413-81232007000400017
Cook R, Calabrese EJ. The importance of hormesis to public health. Cien Saude Colet. 2007 Jul-Aug;12(4):955-63. doi: 10.1590/s1413-81232007000400017. PMID: 17680154.
Copy Download .nbib Format: NLM
[Comprehensive review of type 2 diabetes treatment in primary health care. Hygienic, dietetic, educational and pharmacological aspects].

Enfermeria clinica

Fernández-Duque MV, Maciá-Bobes C, Prida-Villa E, Ronzón-Fernández A.
PMID: 18218266
Enferm Clin. 2008 Jan-Feb;18(1):41-5. doi: 10.1016/s1130-8621(08)70692-2.

Type 2 diabetes is a highly prevalent disease and its management is performed mainly in primary health care. In the present article, focused on the nursing point of view, we propose a comprehensive and very simple approach to the...

Cite
Fernández-Duque MV, Maciá-Bobes C, Prida-Villa E, et al. Revisión integral del tratamiento de la diabetes tipo 2 en atención primaria. Aspectos higienicodietéticos, educacionales y farmacológicos. [Comprehensive review of type 2 diabetes treatment in primary health care. Hygienic, dietetic, educational and pharmacological aspects]. Enferm Clin. 2008;18(1):41-5doi: 10.1016/s1130-8621(08)70692-2.
Fernández-Duque, M. V., Maciá-Bobes, C., Prida-Villa, E., & Ronzón-Fernández, A. (2008). Revisión integral del tratamiento de la diabetes tipo 2 en atención primaria. Aspectos higienicodietéticos, educacionales y farmacológicos. [Comprehensive review of type 2 diabetes treatment in primary health care. Hygienic, dietetic, educational and pharmacological aspects]. Enfermeria clinica, 18(1), 41-5. https://doi.org/10.1016/s1130-8621(08)70692-2
Fernández-Duque, María Violeta, et al. "Revisión integral del tratamiento de la diabetes tipo 2 en atención primaria. Aspectos higienicodietéticos, educacionales y farmacológicos." [Comprehensive review of type 2 diabetes treatment in primary health care. Hygienic, dietetic, educational and pharmacological aspects]. Enfermeria clinica vol. 18,1 (2008): 41-5. doi: https://doi.org/10.1016/s1130-8621(08)70692-2
Fernández-Duque MV, Maciá-Bobes C, Prida-Villa E, Ronzón-Fernández A. Revisión integral del tratamiento de la diabetes tipo 2 en atención primaria. Aspectos higienicodietéticos, educacionales y farmacológicos. [Comprehensive review of type 2 diabetes treatment in primary health care. Hygienic, dietetic, educational and pharmacological aspects]. Enferm Clin. 2008 Jan-Feb;18(1):41-5. doi: 10.1016/s1130-8621(08)70692-2. Spanish. PMID: 18218266.
Copy Download .nbib Format: NLM
'Customized,' 'designer' drugs.

American pharmacy

[No authors listed]
PMID: 6546637
Am Pharm. 1984 Feb;(2):17.

No abstract available.

Cite
'Customized,' 'designer' drugs. Am Pharm. 1984;(2):17
(1984). 'Customized,' 'designer' drugs. American pharmacy, (2), 17.
"'Customized,' 'designer' drugs." American pharmacy vol. ,2 (1984): 17.
'Customized,' 'designer' drugs. Am Pharm. 1984 Feb;(2):17. PMID: 6546637.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 51 entries